Cellular Genomics, Inc. Achieves Key Milestone in Kinase Discovery Program

Strategic Insights -

Cellular Genomics, Inc. (CGI) has announced the completion of a critical performance milestone in its joint kinase discovery program with Serono, a pharmaceutical company. The milestone relates to the successful development of CGI's unique in vivo models for kinase drug discovery, a breakthrough made possible by the company's proprietary chemical genetics Analog Sensitive Kinase (ASKA) technology. This achievement marks a significant step forward in CGI's efforts to apply ASKA to a number of target kinases selected by Serono. The completion of the milestone entitles CGI to a performance payment, further solidifying the company's commitment to innovative kinase drug discovery.

Key Takeaways:

  • CGI has successfully developed 12 in vivo ASKA models spanning multiple kinase families and addressing a broad range of potential clinical indications.
  • The ASKA technology has been utilized to develop an unprecedented in vivo model for kinase drug discovery, enabling pharmaceutically relevant dose- and time-dependent, reversible in vivo inhibition of kinases.
  • CGI's cutting-edge approach to kinases is based on the discovery of ASKAs, which are genetically modified kinases that retain all the functions of normal kinases and can be potently and specifically inhibited by a proprietary small molecule analog inhibitor.
  • The ASKA technology has been applied to a number of target kinases selected by Serono, under the joint kinase discovery program.
  • CGI's achievement has validated the utility of ASKA in kinase drug discovery, as demonstrated by the company's own drug discovery programs at CGI.
  • The partnership with Serono will enable CGI to utilize the unique in vivo models to support kinase drug discovery programs.

Statistics:

  • 12 in vivo ASKA models have been successfully produced, spanning multiple kinase families and addressing a broad range of potential clinical indications.
  • The ASKA technology has been applied to a number of target kinases selected by Serono, under the joint kinase discovery program.
  • The in vivo models developed using ASKA technology make it possible to perform pharmaceutically relevant dose- and time-dependent, reversible in vivo inhibition of kinases.

Sources:

  • Health & Medicine Week editors from staff and other reports.
  • [Source: Health & Medicine Week via NewsRx.com]